Iron-Peptide Complex, formulated by Bioscience Global — a dietary supplement, not a medicine.
Science & Research

What we have studied, and what we have not

Ferravitin's absorption evidence comes from laboratory research. We have not run a randomized, controlled human trial, so we do not say "clinically proven" anywhere on this site.

The bond

Ferravitin uses an Iron-Peptide Complex rather than delivering iron as a mineral salt. The intent is for iron to enter through peptide transport pathways rather than depend solely on the route used by iron salts.

The model

Uptake was measured in an in vitro Caco-2 assay — a cultured human intestinal cell line widely used to screen nutrient absorption. It is a screening model, not a human study.

The limits

The studies presented were uncontrolled, unblinded, and not randomized. Results from laboratory cell models may not predict human outcomes.

Laboratory research

Findings, stated with their source

Absorption was measured in laboratory cell models (in vitro Caco-2). These are cultured intestinal cells, not people.

813%

Greater iron uptake than ferrous sulfate, demonstrated in laboratory cell models (in vitro Caco-2).

<2%

Unabsorbed iron, demonstrated in laboratory cell models (in vitro Caco-2).

[SUBSTANTIATION REQUIRED]

92% absorption, and “14x more entry points”, both require human pharmacokinetic data or a cited published study before use.

[REMOVED]

Comparisons of 471% versus bisglycinate and 354% versus heme iron are not shown — no cited study supports either figure.

Results from laboratory cell models may not predict human outcomes. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

[CITATION REQUIRED] Louisiana State University Iron-Peptide Complex uptake study, 2018 — in vitro Caco-2 cell model

Needs full author list, journal title, volume, issue, pages, and DOI before this reference can be published. Labelled here as an in vitro cell model study; the “landmark” characterisation has been removed.

[CITATION REQUIRED] Internal observational lab results 1 & 2

Small, uncontrolled observational series. Needs sample size, protocol, endpoints, and publication status. Cannot support “clinically proven” language.

[CITATION REQUIRED · SCOPE CHANGED] JAMA Network, September 2024 — iron status literature

Needs full citation with volume and DOI. The previous heart-failure framing has been removed from all commercial context; if retained, this belongs in a clearly separated educational section stating that Ferravitin does not treat any disease.

Educational references describe the published science on iron and normal body function. They are not claims about Ferravitin. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.